Citius Oncology (NASDAQ:CTOR) Shares Up 3.6% - What's Next?

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Shares of Citius Oncology, Inc. (NASDAQ:CTOR - Get Free Report) shot up 3.6% during mid-day trading on Monday . The stock traded as high as $1.81 and last traded at $1.75. 100,206 shares were traded during trading, a decline of 93% from the average session volume of 1,520,231 shares. The stock had previously closed at $1.69.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on CTOR. Citigroup downgraded Citius Oncology to a "hold" rating in a report on Friday, May 23rd. Wall Street Zen upgraded Citius Oncology to a "hold" rating in a report on Saturday, July 26th. Finally, Maxim Group downgraded Citius Oncology from a "strong-buy" rating to a "hold" rating in a report on Friday, May 23rd. Two equities research analysts have rated the stock with a Hold rating, According to data from MarketBeat.com, Citius Oncology has an average rating of "Hold" and a consensus price target of $3.00.

Citius Oncology Stock Up 7.4%

The stock has a 50 day moving average of $2.46 and a 200 day moving average of $1.45. The company has a debt-to-equity ratio of 0.12, a quick ratio of 0.02 and a current ratio of 0.35.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the stock. Bank of America Corp DE grew its stake in Citius Oncology by 5,256.9% during the 2nd quarter. Bank of America Corp DE now owns 8,571 shares of the company's stock worth $37,000 after buying an additional 8,411 shares during the last quarter. Jane Street Group LLC bought a new position in Citius Oncology during the 2nd quarter worth $465,000. Geode Capital Management LLC grew its stake in Citius Oncology by 179.0% during the 2nd quarter. Geode Capital Management LLC now owns 57,297 shares of the company's stock worth $249,000 after buying an additional 36,758 shares during the last quarter. Arkadios Wealth Advisors acquired a new position in Citius Oncology during the 2nd quarter worth $51,000. Finally, Citadel Advisors LLC acquired a new position in Citius Oncology during the 4th quarter worth $26,000. 70.52% of the stock is currently owned by institutional investors.

Citius Oncology Company Profile

Citius Oncology, Inc is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma.